PMID- 29682177
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210111
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 9
IP  - 24
DP  - 2018 Mar 30
TI  - Chemerin induces endothelial cell inflammation: activation of nuclear 
      factor-kappa beta and monocyte-endothelial adhesion.
PG  - 16678-16690
LID - 10.18632/oncotarget.24659 [doi]
AB  - Chemerin, a chemoattractant protein, acts via a G-protein coupled chemokine 
      receptor, i.e. Chemokine like Receptor 1/ChemR23; levels of which are elevated in 
      pro-inflammatory states such as obesity and type 2 diabetes mellitus (T2DM). 
      Obesity and T2DM patients are at high risk of developing cardiovascular disorders 
      such as atherosclerosis. We have reported that chemerin induces human endothelial 
      cell angiogenesis and since dysregulated angiogenesis and endothelial dysfunction 
      are hallmarks of vascular disease; we sought to determine the effects of chemerin 
      on monocyte-endothelial adhesion, and nuclear factor kappa-light-chain-enhancer 
      of activated B cells (NF-kappaB), a critical pro-inflammatory transcription factor. 
      Human endothelial cells were transfected with pNF-kappaB-Luc plasmid. Chemerin 
      induced NF-kappaB activation via the MAPK and PI3K/Akt pathways. Western blot 
      analyses and monocyte-endothelial adhesion assay showed that chemerin increased 
      endothelial cell adhesion molecule expression and secretion, namely E-selectin 
      (Endothelial Selectin), VCAM-1 (Vascular Cell Adhesion Molecule-1) and ICAM-1 
      (Intracellular Adhesion Molecule-1), leading to enhancement of 
      monocyte-endothelial adhesion. Additionally, we showed a synergistic response of 
      the pro-inflammatory mediator, Interleukin-1beta with chemerin induced effects. 
      Chemerin plays an important role in endothelial inflammation, as it induces 
      monocyte-endothelial adhesion, a critical step in the development of 
      atherosclerosis.
FAU - Dimitriadis, Georgios K
AU  - Dimitriadis GK
AD  - Division of Translational and Experimental Medicine, Warwick Medical School, 
      University of Warwick, Coventry, UK.
AD  - Division of Endocrinology and Experimental Medicine, Imperial College London, 
      Hammersmith Campus, London, UK.
AD  - WISDEM Centre, Human Metabolism Research Unit, University Hospitals Coventry and 
      Warwickshire NHS Trust, Coventry, UK.
FAU - Kaur, Jaspreet
AU  - Kaur J
AD  - Division of Translational and Experimental Medicine, Warwick Medical School, 
      University of Warwick, Coventry, UK.
AD  - Division of Biomedical Sciences, School of Medicine, University of California, 
      Riverside, CA, USA.
FAU - Adya, Raghu
AU  - Adya R
AD  - Division of Translational and Experimental Medicine, Warwick Medical School, 
      University of Warwick, Coventry, UK.
FAU - Miras, Alexander D
AU  - Miras AD
AD  - Division of Endocrinology and Experimental Medicine, Imperial College London, 
      Hammersmith Campus, London, UK.
FAU - Mattu, Harman S
AU  - Mattu HS
AD  - Division of Translational and Experimental Medicine, Warwick Medical School, 
      University of Warwick, Coventry, UK.
FAU - Hattersley, John G
AU  - Hattersley JG
AD  - WISDEM Centre, Human Metabolism Research Unit, University Hospitals Coventry and 
      Warwickshire NHS Trust, Coventry, UK.
FAU - Kaltsas, Gregory
AU  - Kaltsas G
AD  - WISDEM Centre, Human Metabolism Research Unit, University Hospitals Coventry and 
      Warwickshire NHS Trust, Coventry, UK.
FAU - Tan, Bee K
AU  - Tan BK
AD  - Division of Translational and Experimental Medicine, Warwick Medical School, 
      University of Warwick, Coventry, UK.
AD  - Department of Obstetrics and Gynaecology, Birmingham Heartlands Hospital, Heart 
      of England NHS Foundation Trust, Birmingham, UK.
FAU - Randeva, Harpal S
AU  - Randeva HS
AD  - Division of Translational and Experimental Medicine, Warwick Medical School, 
      University of Warwick, Coventry, UK.
AD  - WISDEM Centre, Human Metabolism Research Unit, University Hospitals Coventry and 
      Warwickshire NHS Trust, Coventry, UK.
AD  - Division of Life and Health Sciences, Aston University, Birmingham, UK.
LA  - eng
GR  - G0902002/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
DEP - 20180330
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
PMC - PMC5908278
OTO - NOTNLM
OT  - T2DM
OT  - atherosclerosis
OT  - chemerin
OT  - endothelium
OT  - inflammation
COIS- CONFLICTS OF INTEREST No potential conflicts of interest.
EDAT- 2018/04/24 06:00
MHDA- 2018/04/24 06:01
PMCR- 2018/03/30
CRDT- 2018/04/24 06:00
PHST- 2018/01/15 00:00 [received]
PHST- 2018/02/27 00:00 [accepted]
PHST- 2018/04/24 06:00 [entrez]
PHST- 2018/04/24 06:00 [pubmed]
PHST- 2018/04/24 06:01 [medline]
PHST- 2018/03/30 00:00 [pmc-release]
AID - 24659 [pii]
AID - 10.18632/oncotarget.24659 [doi]
PST - epublish
SO  - Oncotarget. 2018 Mar 30;9(24):16678-16690. doi: 10.18632/oncotarget.24659. 
      eCollection 2018 Mar 30.